MoonLake Immunotherapeutics (MLTX) stock
MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.25−0.48 (-4.09%)
Close on Nov 17, 2026Market cap $957.45MP/E –Yield –
MoonLake Immunotherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
MoonLake Immunotherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$225.18M. For fiscal 2025 it was -$196.01M. The highest annual figure on record is -$611.07K in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$196.01M | – |
| FY2024 | Dec 31, 2024 | -$116.59M | – |
| FY2023 | Dec 31, 2023 | -$42.78M | – |
| FY2022 | Dec 31, 2022 | -$55.89M | – |
| FY2021 | Dec 31, 2021 | -$611.07K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$55.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$66.29M | – |
| Q4 FY2025 | Dec 31, 2025 | -$58.79M | – |
| Q3 FY2025 | Sep 30, 2025 | -$44.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$54.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$38.14M | – |
| Q4 FY2024 | Dec 31, 2024 | -$48.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.28M | – |
| Q2 FY2024 | Jun 30, 2024 | -$27.89M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.95M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.34M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.60M | -142.8% |
| Q3 FY2022 | Sep 30, 2022 | -$9.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.19M | – |
| Q4 FY2021 | Dec 31, 2021 | $27.11M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$25.60M | – |
| Q1 FY2021 | Mar 31, 2021 | -$107.80K | – |
See a number that looks wrong?